Search bioRxiv⌕ Search

Biology subjects

R, K.

Publications and source records attributed to R, K..

6 recordsLinked to original sources

Prediction of Systemic Lupus Erythematosus from Genotype and1 Gene-Expression Data: Batch Correction and Leakage Free2 Evaluation

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease with a strong genetic component and highly variable clinical features. Because of this heterogeneity, predicting disease status remains challenging using any single marker alone. In this study, we explore two complementary data sources: (1) genotypes at 30 candidate SNPs in a South Indian case-control cohort (n = 425) and (2) bulk expression of 13 genes from the same pathways, curated from six GEO series (n = 642 SLE or control samples from 483 individuals), to investigate whether they can distinguish SLE cases from healthy controls. The expression data were placed on a common log2 scale and corrected for batch effects using mean-only ComBat. To avoid data leakage, ComBat, gene filtering, scaling, and model fitting were re-estimated within every training fold, and all samples from the same individual were kept in the same fold. Performance was summarised using ROC-AUC, precision-recall AUC (PR-AUC), and the Matthews correlation coefficient (MCC) over 10 x 5-fold cross-validation. Models were interpreted using out-of-fold SHAP values, and the entire pipeline was evaluated using label permutations. For the SNP data, dominant encoding with age and sex gave ROC-AUC 0.699 {+/-} 0.052, PR-AUC 0.668 {+/-} 0.063, and MCC 0.309 {+/-} 0.101. However, this performance depended on four SNPs that deviated from Hardy-Weinberg equilibrium in controls. Without these SNPs, the SNPs added little predictive value beyond age and sex (ROC-AUC 0.656). The strongest single association, at MTRR A66G, resulted from an excess of heterozygotes among controls, a pattern typical of genotyping error. In contrast, homozygous CYP1A1 M2 and COMT genotypes, as well as CYP1A1 M4 carriers, were enriched in cases, pointing to a possible role for xenobiotic metabolism. The leakage-free expression classifiers achieved ROC-AUC values of 0.837 {+/-} 0.033 for L1-penalised logistic regression and 0.915 {+/-} 0.021 for XGBoost. Shuffled labels produced chance-level results, supporting the absence of label leakage in the pipeline. However, a model using only the study label achieved an ROC-AUC of 0.857, indicating strong confounding between disease status and study identity. Within individual studies, ROC-AUC was 0.743 for L1-penalised logistic regression and 0.835 for XGBoost. Performance fell to 0.46-0.74 when entire studies were held out. Lower MTR expression was the most important and consistent expression feature, whereas two other highly ranked genes, CYP1A1 and GSTT1, carried little predictive signal within individual studies. These findings show that, in pooled multi-study expression data, leakage-free cross-validation alone does not guarantee reliable performance estimates. Batch-label confounding and genotype quality must also be assessed directly.

genomics↗

Modulation of H3K4 trimethylation by KDM5A and MLLs impacts metabolic adaptability in prostate and cervical cancer cells

AbstractChemical modifications of chromatin modulate gene expression and induce essential metabolic plasticity for tumor growth. Accumulation of H3K4me3 in the promoter of a gene activates transcription by making the promoter accessible to the polymerases. Methylation of H3K4 is catalysed by MLLs and demethylation of H3K4me3 is catalysed by KDM5 family proteins. Herein, we investigated if genes encoding the enzymes involved in glucose metabolism are dependent on KDM5A and MLL1, and if targeting the H3K4me3 would help in modulating the resilience of cancer cells. We present that KDM5A modulates most of the metabolic genes in a demethylase dependent manner as assesses by H3K4me3 occupancy on G6PD and catalase promoters. Targeting its expression would indeed help in sensitizing cancer cells to ROS dependent apoptotic cell death. We elucidated the differences in the epigenetic regulation in cancerous cells originated from cervical and prostate tissues and used a normal skin keratinocyte for comparison. In cervical and prostate cancers - KDM5A activated glycolysis but downregulates other metabolic processes. In cervical cancer, which majorly depends on PPP, changes in KDM5A did not modulate the G6PD expression. Further, we have shown that curcumin treatment enhanced KDM5A expression and downregulated MLL2 in cancer cell lines but not in keratinocyte cells. Curcumin inhibited metabolic pathways and enhanced apoptosis in cancer cells without affecting keratinocyte cells by modulating KDM5A and MLL levels. This work also strengthens the basic concept that, epigenetic modulations of genes in a tissue precisely depends on signal and sites of modification(s).

cancer biology↗

MyeloDB: A multi-omics resource for Multiple Myeloma

Multiple myeloma (MM) is a common type of blood cancer affecting plasma cells originating from the lymphoid B-cell lineage. It accounts for about 10% of all haematological malignancies and can cause significant end-organ damage. The emergence of genomic technologies such as next-generation sequencing and gene expression analysis has opened new possibilities for early detection of multiple myeloma and identification of personalized treatment options. However, there remain significant challenges to overcome in MM research, including integrating multi-omics data, achieving a comprehensive understanding of the disease, and developing targeted therapies and biomarkers. The extensive data generated by these technologies presents another challenge for data analysis and interpretation. To bridge this gap, we have developed a multi-omics open-access database called MyeloDB. It includes gene expression profiling, high throughput CRISPR-Cas9 screens, drug sensitivity resources profile, and biomarkers. MyeloDB contains 47 expression profiles, 3 methylation profiles comprising a total of 5630 patient samples and 15 biomarkers which were reported in previous studies. In addition to this, MyeloDB can provide significant insight of gene mutations in MM on drug sensitivity. Furthermore, users can download the datasets and conduct their own analyses. Utilizing this database, we have identified five novel genes i.e., CBFB, MANF, MBNL1, SEPHS2 and UFM1 as potential drug targets for MM. We hope MyeloDB will serve as a comprehensive platform for researchers and foster novel discoveries in MM. MyeloDB is freely accessible at: (https://project.iith.ac.in/cgntlab/myelodb/)

genomics↗

AMLdb: A comprehensive multi-omics platform to understand the pathogenesis and discover biomarkers for acute myeloid leukemia

Acute myeloid leukemia (AML) is one of the leading leukemic malignancies in adults. The heterogeneity of the disease makes the diagnosis and treatment extremely difficult. Despite the significant developments and the rapid advancements in finding new medication targets, the treatment for AML remains a challenge. With the advent of next-generation sequencing (NGS) technologies, exploration at the molecular level for the identification of biomarkers and drug targets has been the main focus for the researchers to come up with novel therapies for better prognosis and survival outcomes of AML patients. However, the massive amounts of data generated from the NGS platforms demands the necessity to create a comprehensive platform on AML to save the time invested in mining literature. To facilitate this, we developed AMLdb, an interactive multi-omics platform that allows users to query, visualize, retrieve and analyze AML-related multi-omics data. It provides a diverse collection of data resourced from various repositories allowing for a more comprehensive analysis. AMLdb contains 86 datasets for gene expression profiles, 15 datasets for methylation profiles, CRISPR-Cas9 knockout screens of 26 AML cell lines, sensitivity of 26 AML cell lines to 288 drugs, mutations in 41 unique genes in 23 AML cell lines and information on 27 experimentally validated biomarkers. The data provided can be used for deriving conclusions on potential targets for therapies, sensitivity of these targets towards the drugs, patient classification, prediction of treatment strategies and outcomes, chances of relapse etc. In this study, we have reported five genes i.e., CBFB, ENO1, IMPDH2, SEPHS2 and MYH9 identified via our analysis using AMLdb as potential targets. Amongst this, CBFB, IMPDH2, SEPHS2 and MYH9 have been previously validated as targets by experimental studies which is in par with our results. However, ENO1 is a novel target identified using AMLdb which needs further investigation. We anticipates that, AMLdb can be a valuable resource to aid the research community accelerate the development of effective therapies for AML. AMLdb is freely accessible at https://project.iith.ac.in/cgntlab/amldb/ without any restrictions.

genomics↗

Physical association of functionally antagonistic enzymes: KDM5A interacts with MLLs to regulate gene expression in a promoter specific manner facilitating EMT and pluripotency.

Differential expression of genes involved in physiological processes are a collaborative outcome of interactions among signalling molecules, downstream effectors and epigenetic modifiers, which together dictate the regulation of genes in response to specific stimuli. MLLs and KDM5A are functionally antagonistic proteins as one acts as writer and the other as eraser of the active chromatin mark, i.e., H3K4me3. KDM5A promotes EMT by occupying promoters of both epithelial and mesenchymal markers. Through this work, it is illustrated that when bound to E-cadherin promoter, KDM5A acts as a classical repressor by demethylating H3K4me3, but on mesenchymal marker promoters, it acts as a transcriptional activator by inhibiting the activity of HDACs and increasing H3K18ac. Further it is demonstrated that KDM5A occupancy enhances either MLL1 or MLL2 by physically interacting with them and that signalling pathways regulate the enzymatic activity of KDM5A probably by phosphorylation. When not active, KDM5A signals for MLL occupancy, a mechanism that can be called epigenetic signalling.

molecular biology↗

STIL a novel link in Shh and Wnt signaling, endowing oncogenic and stem like attributes to colorectal cancer

Discovery of potent gene regulating tumorigenesis and drug resistance is of high clinical importance. STIL is an oncogene, however its molecular insights and role in colorectal oncogenesis are unknown. In this study we have explored role of STIL in tumorigenesis and studied its molecular targets in colorectal cancer (CRC). STIL silencing reduced proliferation and tumor growth in CRC. Further, STIL was found to regulate stemness markers CD133 & CD44 and drug resistant markers Thymidylate synthase, ABCB1 & ABCG2 both in in-vitro and in-vivo CRC models. In addition, over expression of STIL mRNA was found to be associated with reduced disease free survival in CRC cases. To our surprise we observed an Shh independent regulation of stemness and drug resistant genes mediated by STIL. Interestingly, we found an Shh independent regulation of {beta}-catenin mediated by STIL via p-AKT, which partially answers Shh independent regulatory mechanism of CSC markers by STIL. Our study suggest an instrumental role of STIL in molecular manifestation of CRC and progression.

cancer biology↗